Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy.

Trial Profile

Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 May 2017

At a glance

  • Drugs Olaparib (Primary)
  • Indications Ewing's sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Mar 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 05 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 04 Jun 2012 Actual initiation date (May 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top